Melbourne, Australia, 28 April 2019: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce that we will be presenting at the Association for Research in Vision and Ophthalmology (ARVO).
OccuRx will present its new research titled ‘Oral administration of the novel small molecule drug OCX063 protects against inflammation and vascular pathology in a rat diabetic retinopathy (DR) model’ during the conference held from 28th April – 2nd May 2019 in Vancouver, Canada.
The presentation will demonstrate that orally administered OCX063 prevents retinal inflammation and vascular pathology in a model of DR, highlighting its potential for treating proliferative retinal diseases. Given OCX063’s favourable efficacy and safety profile, this compound is expected to be translated into a Phase I clinical trial as it proceeds into the next stage of development.
“We are delighted to present promising preclinical results that show efficacy of the anti-fibrotic drug candidate, OCX063, in a diabetic retinopathy model.” said Professor Darren Kelly, Executive Chair of OccuRx.“Diabetic retinopathy (DR) is the main cause of vision loss among adults and is associated with neuroinflammation, vascular pathology and ultimately, fibrosis so we’re excited to present this data and progress with our drug candidate that has the potential to have retinoprotective effects in an established model of DR.”.
The full paper reference for this research can be found below.
Paper publication reference:
Roy Chze Khai Kong, A Edgley, E Chan, AJ Cox, S Glowacka, M Papadimitriou, FL Khong, D Kelly.” Oral administration of the novel small molecule drug OCX063 protects against inflammation and vascular pathology in a rat diabetic retinopathy (DR) model” Investigative Ophthalmology & Visual Science July 2019, Vol.60(9), 5356
